Illumina is teaming up with Tempus AI for a project aimed at promoting the use of DNA sequencing tests across all major areas of disease. | The companies said they will work together to train ...

Gain precise, in-depth insights into microbial genomes with Illumina’s comprehensive Methods for Microbial Single-Genome Sequencing guide.

Ultima Genomics announces that it will provide three trillion DNA sequencing reads free of charge to researchers across the ...

Designed for ease of use and efficiency, our guide highlights the benefits of small oncology panels, including faster turnaround times, cost-effective sequencing, and simplified data analysis. With an ...

The San Diego company also lowered its financial guidance for 2025 in response to China’s import restrictions.

Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to ...

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country.

Illumina shareholders received a warning shot. In response to President Trump’s initial tariff measures, the Chinese government added the maker of gene-sequencing equipment to its list of “unreliable ...

Illumina (ILMN) and Tempus AI (TEM) announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel ...

(NASDAQ:ILMN). Illumina, Inc. (NASDAQ:ILMN) offers sequencing- and array-based solutions for genetic and genomic analysis. The one-month return of Illumina, Inc. (NASDAQ:ILMN) was -32.97% ...

Business: Illumina provides sequencing-and array-based solutions for genetic and genomic analysis. It offers products and services to customers in a range of markets, enabling the adoption of genomic ...

Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing market is expected to grow by 14.90%-21.65% CAGR in the following ten years. Despite the losses ...